To evaluate the effectiveness and safety of arbidol in preventing and treating influenza in adults and children.1 Arbidol for preventing and treating influenza in adults and children (Protocol)
The article includes the results of comparative study of uterine scar after cesarean section depending on the time of surgery – at term pregnancy or during the term labor. There was more intense neoangiogenesis in the uterine wound at early postoperative period and the number of patients with morphologically “sufficient” uterine scar increased in 2 times when cesarean section was performed at term labor.
also calculated. All costs were inflated to 2010 US$. RESULTS: Data were available for 900 employees (HCV-Txϭ216;HCV-noTxϭ684). The cohorts differed in salaries, the %married, %white, and %exempt. Mean HCV-noTx cohort IN ($836,Pϭ0.0001) and OUT ($488,Pϭ0.0018) costs were higher, and HCV-Tx MD ($564, PϽ0.0001), LAB ($42,PϽ0.0001) and Rx ($21,420,PϽ0.0001) costs were higher. The HCV-noTx cohort had more IN services (1.83, Pϭ0.0021), while the HCV-Tx cohort had more MD (15.48,PϽ0.0001), LAB (3.31,PϽ0.0001) and Rx (12.0,PϽ0.0001) services. Overall, HCV-Tx direct medical costs were $3556 (servicesϭ54.40) which were lower than the HCV-noTx ($4234;servicesϭ35.39). The HCV-Tx cohort had 27.84 Rxs ($22,726) vs the HCV-noTx cohort's 15.84 Rxs ($1408). CONCLUSIONS: Higher costs associated with HCV Treatment in the MD office offset IN and OUT costs. OBJECTIVES:To determine if subsets of gastroesophageal reflux disease (GERD) patients vary with respect to healthcare utilization. METHODS: This retrospective analysis identified commercial enrollees 18-75 years old with claims for GERD (ICD-9-CM: 530.81 or 530.11) and proton pump inhibitors (PPI) during 01/01/05 -06/30/09. Patients were further required to have no claims for HIV, pregnancy, inflammatory bowel disease or cancer at any time, or GERD prescription or gastric/duodenal ulcer prior to initial GERD diagnosis. Eligible patients were then stratified based on medical claims for other symptoms during a 12 month period centered on their first GERD diagnosis: Stage A (GERD diagnosis, no other symptoms); Stage B (GERD ϩ respiratory symptoms); Stage C (GERD ϩ Barrett's esophagus); Stage D (GERD ϩ esophageal stricture); Stage E (GERD ϩ iron deficiency anemia or acute hemorrhage). The stages were compared with respect to GERD treatment, other gastrointestinal symptoms and GERD-related or all-cause costs for outpatient, inpatient, and pharmacy care during the first six months after initial diagnosis using univariate statistics. RESULTS: 174,597 patients were analyzed: Stage A: 74%, Stage B: 20%, Stage C: 1%, Stage D: 2%, Stage E: 3%. Versus stages A and B, patients in Stages C-E were more likely to visit a gastroenterologist (53.9% vs. 12.9%), receive multiple PPI (11.5% vs. 7.4%) and had higher rates of gastritis/duodenitis (17.0% vs. 5.9%), esophageal ulcers (4.4% vs. 0.3%), and esophageal surgery (7.6% vs. 0.3%). Six month GERD-related costs ranged from $615/patient (Stage A) to $1,714/patient (Stage D); all-cause costs ranged from $4,195/patient (Stage A) to $11,340/patient (Stage E) (pϽ0.0001 for all contrasts). CONCLUSIONS: While GERD patients with additional complications represented a relatively small portion of the total sample, their significantly higher costs and events suggest an opportunity for improving patient care.
also calculated. All costs were inflated to 2010 US$. RESULTS: Data were available for 900 employees (HCV-Txϭ216;HCV-noTxϭ684). The cohorts differed in salaries, the %married, %white, and %exempt. Mean HCV-noTx cohort IN ($836,Pϭ0.0001) and OUT ($488,Pϭ0.0018) costs were higher, and HCV-Tx MD ($564, PϽ0.0001), LAB ($42,PϽ0.0001) and Rx ($21,420,PϽ0.0001) costs were higher. The HCV-noTx cohort had more IN services (1.83, Pϭ0.0021), while the HCV-Tx cohort had more MD (15.48,PϽ0.0001), LAB (3.31,PϽ0.0001) and Rx (12.0,PϽ0.0001) services. Overall, HCV-Tx direct medical costs were $3556 (servicesϭ54.40) which were lower than the HCV-noTx ($4234;servicesϭ35.39). The HCV-Tx cohort had 27.84 Rxs ($22,726) vs the HCV-noTx cohort's 15.84 Rxs ($1408). CONCLUSIONS: Higher costs associated with HCV Treatment in the MD office offset IN and OUT costs. OBJECTIVES:To determine if subsets of gastroesophageal reflux disease (GERD) patients vary with respect to healthcare utilization. METHODS: This retrospective analysis identified commercial enrollees 18-75 years old with claims for GERD (ICD-9-CM: 530.81 or 530.11) and proton pump inhibitors (PPI) during 01/01/05 -06/30/09. Patients were further required to have no claims for HIV, pregnancy, inflammatory bowel disease or cancer at any time, or GERD prescription or gastric/duodenal ulcer prior to initial GERD diagnosis. Eligible patients were then stratified based on medical claims for other symptoms during a 12 month period centered on their first GERD diagnosis: Stage A (GERD diagnosis, no other symptoms); Stage B (GERD ϩ respiratory symptoms); Stage C (GERD ϩ Barrett's esophagus); Stage D (GERD ϩ esophageal stricture); Stage E (GERD ϩ iron deficiency anemia or acute hemorrhage). The stages were compared with respect to GERD treatment, other gastrointestinal symptoms and GERD-related or all-cause costs for outpatient, inpatient, and pharmacy care during the first six months after initial diagnosis using univariate statistics. RESULTS: 174,597 patients were analyzed: Stage A: 74%, Stage B: 20%, Stage C: 1%, Stage D: 2%, Stage E: 3%. Versus stages A and B, patients in Stages C-E were more likely to visit a gastroenterologist (53.9% vs. 12.9%), receive multiple PPI (11.5% vs. 7.4%) and had higher rates of gastritis/duodenitis (17.0% vs. 5.9%), esophageal ulcers (4.4% vs. 0.3%), and esophageal surgery (7.6% vs. 0.3%). Six month GERD-related costs ranged from $615/patient (Stage A) to $1,714/patient (Stage D); all-cause costs ranged from $4,195/patient (Stage A) to $11,340/patient (Stage E) (pϽ0.0001 for all contrasts). CONCLUSIONS: While GERD patients with additional complications represented a relatively small portion of the total sample, their significantly higher costs and events suggest an opportunity for improving patient care.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.